

Alyglo Assist

YOUR ALLY IN IVIG

Support for you
and your patients,
right from the start.

ALYGLO® is a glycine-stabilized immune globulin, intravenous, human-stwk 10% liquid indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE

- Thrombosis may occur with immune globulin intravenous (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
- Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients.
- Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction or renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Please see additional Important Safety Information throughout, and accompanying full Prescribing Information inside pocket.

 **Alyglo**®
immune globulin
intravenous, human-stwk
10% liquid

Alyglo Assist

YOUR ALLY IN IVIG

At GC Biopharma, we're committed to providing seamless support throughout your patients' journeys, from helping to get them started on treatment without delays to ongoing education and clinical support.

Every step of the journey, we're here for you.

One-Stop Access Portal

We utilize a single portal designed specifically for IG therapies to help streamline support needs, from prescription to administration.

- If you already have a MedMonk login, no need to re-register
- Use your current login credentials, enter your patients' information, and we'll take care of the rest



Visit alyglo.medmonk.com to get started.

Coding and Billing Instructions for ALYGLO® immune globulin intravenous, human-stwk, 10% liquid

HCPCS Code: J1552 (2 units = 1 gram)

For more details, please visit hcp.alyglo.com/starting_patients

Coding and billing requirements vary across different payers and are subject to change. Before billing for ALYGLO, providers should always check with individual payers to determine their coding requirements.

IMPORTANT SAFETY INFORMATION, cont.

Contraindications: ALYGLO is contraindicated in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.

Please see additional Important Safety Information throughout, and accompanying full Prescribing Information inside pocket.

ALYGLO Co-Pay Program

- Eligible patients with commercial insurance can receive up to a total benefit of \$15,000 per calendar year, for the deductible, co-pay, and/or coinsurance for ALYGLO
- Can be used regardless of whether billing is through a major medical plan or pharmacy benefits

Eligibility Criteria for Co-Pay Assistance:

Patient must be a US resident

Patient must express financial need

Assistance is available to commercially insured patients only

Restrictions:

- Assistance covers only out-of-pocket expenses for the drug portion; administration supplies and nursing co-pay costs are not covered through the program
- Patients are ineligible for co-pay assistance if they participate in Medicare, Medicaid, Medigap, Veteran Affairs, Department of Defense, Tricare, or any other federal or state-funded programs.

ELIGIBLE PATIENTS
MAY PAY AS
LITTLE AS
\$0 OUT OF
POCKET

Terms, conditions, and eligibility requirements apply. See alyglo.medmonk.com for full details.



Understanding Benefits

Commercial coverage plans can be complex. We can help verify benefits, so you and your patients can better understand what's covered. We can also provide guidance as to whether you should file your claim as a pharmacy or medical benefit.



Prior Authorization Assistance

We offer dedicated help to effectively navigate lengthy prior authorization processes and help patients get started on treatment



Reimbursement Support

Our teams can help with reimbursement claims and help guide you through any questions and concerns



Help Getting Started

Our team will help establish a connection with care providers for home infusions

Call 1-888-501-8040 or visit alyglo.medmonk.com for support

Alyglo[®]
immune globulin
intravenous, human-stwk
10% liquid

Alyglo Assist

YOUR ALLY IN IVIG

Education and Support



Patient Resources

We'll provide materials to help your patient better understand their disease and what to expect during treatment.

Patients can learn more at www.ALYGLO.com



Clinical Support

Our Medical Affairs team is available for clinical inquiries. As our partner, you also have access to medical experts in immunology.

We offer education, training, and support for infusion nurses.

Call 1-833-426-6426 or email medicalinfo@gcbiopharmausa.com

IMPORTANT SAFETY INFORMATION, cont.

- **Hypersensitivity:** In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions.
- **Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia:** Hyperproteinemia, increased serum viscosity, and hyponatremia may occur.
- **Aseptic Meningitis Syndrome (AMS):** Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion. AMS usually begins within several hours to 2 days following ALYGLO treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae.
- **Hemolysis:** Delayed hemolytic anemia due to enhanced red blood cell (RBC) sequestration and acute hemolysis consistent with intravascular hemolysis have been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors.
- **Transfusion-Related Acute Lung Injury:** Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Patients with TRALI may be managed using oxygen therapy with adequate ventilator support. Monitor patients for pulmonary adverse reactions.
- **Transmissible Infectious Agents:** Because ALYGLO is made from human blood, it may carry a risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
- **Interference with Laboratory Tests:** After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for a misleading interpretation.
- **Adverse reactions** (observed in $\geq 5\%$ of study subjects) were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness.
- It is recommended that ALYGLO be administered separately from other drugs or medications.

Please see additional Important Safety Information on previous pages and full Prescribing Information inside pocket.

